FDA Approves New Imaging System to Enhance Cervical Cancer Detection

Publication
Article
OncologyONCOLOGY Vol 22 No 14
Volume 22
Issue 14

BD Diagnostics recently announced that it received US Food and Drug Administration (FDA) Premarket Approval for the BD FocalPoint GS Imaging System.

BD Diagnostics recently announced that it received US Food and Drug Administration (FDA) Premarket Approval for the BD FocalPoint GS Imaging System. This innovative new system is designed to enhance cervical cancer screening for cytology laboratories using the BD SurePath Pap test slides to detect evidence of squamous carcinoma, adenocarcinoma and their usual precursor conditions.

Articles in this issue
The Absent-Minded Professor: An Unusual Complication of Melanoma
The Absent-Minded Professor: An Unusual Complication of Melanoma
Inflammatory Breast Cancer: A Complex Disease
Defining the IBC Phenotype
Acupuncture
Acupuncture
Two Orphan Drug Designations Granted for Reviroc in NHL
NDA Submitted for Trabectedin to Treat Relapsed Ovarian Cancer
FDA Considers Update for Tanning Bed Labels
FDA Approves New Imaging System to Enhance Cervical Cancer Detection
Fostamatinib Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia
Dexamethasone in Induction Can Eliminate One-Third of All Relapses in Childhood Acute Lymphoblastic Leukemia
Novel Antifolate Pralatrexate Shows Promise in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Alemtuzumab May Lead to Longer Overall Survival in CLL Patients With Poor Prognostic Factors
21st Century Challenge of Ovarian Cancer in the Elderly
21st Century Challenge of Ovarian Cancer in the Elderly
Molecular Determinants of the Inflammatory Breast Cancer Phenotype
Recent Videos
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Related Content
Results from the phase 3 KEYNOTE-B96 trial showed favorable results with pembrolizumab-based therapy in this ovarian cancer population.

Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC

Tim Cortese
October 18th 2025
Article

Results from the phase 3 KEYNOTE-B96 trial showed favorable results with pembrolizumab-based therapy in this ovarian cancer population.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

The most pronounced overall and recurrence-free survival benefit with chemoradiotherapy was observed among patients with P53 abnormal endometrial cancer.

Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer

Roman Fabbricatore
October 13th 2025
Article

The most pronounced overall and recurrence-free survival benefit with chemoradiotherapy was observed among patients with TP53-abnormal endometrial cancer.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

ONCOLOGY Staff
September 27th 2025
Article

Karen Kehl shares her decade-long journey with multiple myeloma, discussing treatment options and the impact of bispecific antibodies like talquetamab with Binod Dhakal, MD.

Multidisciplinary Team Discusses Practical Treatment Options in NSCLC

Multidisciplinary Team Discusses Practical Treatment Options in NSCLC

ONCOLOGY Staff
September 26th 2025
Article

Experts at City of Hope explore innovative immunotherapy strategies for non-small cell lung cancer, highlighting efficacy and toxicity management in treatment.